Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction - DAPT-SHOCK-AMI study (PRAGUE-23)

Fakultní nemocnice Královské Vinohrady0 个研究点目标入组 40 人开始时间: 2019年4月15日最近更新: 2023年9月4日

适应症

试验速览

暂无简介。

•1. Age more than 18
•2. Acute myocardial infarction as per ESC/ACC/AHA23 indicated to emergency percutaneous coronary intervention (primary PCI strategy)
•3. Cardiogenic shock resulting from acute myocardial infarction in admission (occurence of two or more of the following criteria):
•- systolic blood preassure < 90mmHg
•- necessity of vasopressor and/or inotropes use
•- signs of organ perfusion - cyanosis, cold body extremities, unconsciousness, congestive heart failure
•4. Signed informed consent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 304
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 304

•1. Contraindication to anti-platelet ticagrelor/cangrelor treatment
•- recent (< 6 months) major bleeding
•-recent (< 1 month) major surgery/injury
•-intracranial bleeding in anamnesis
•-stroke/TIA in anamnesis
•-Ticagrelor/Cangrelor intolerance
•-serious liver indeficiency
•-concomitant use of CYP3A4 inhibitor (eg. ketokonazole, clarithromycin, nefazodon, ritonavir, atazanavir)
•2. Oral use of P2Y12 inhibitor before admission (Clopidogrel = 300mg, Ticagrelor 180 mg, Prasugrel 60 mg)
•3. Necessity of concomitant chronic anticoagulant treatment for atrial fibrillation, artificial valve, tromboembolism etc.)

发起方